Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
Blood Research
;
: 187-192, 2016.
Article
Dans Anglais
| WPRIM
| ID: wpr-209254
ABSTRACT
BACKGROUND:
This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs).METHODS:
Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed.RESULTS:
The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality.CONCLUSION:
IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Thrombopénie
/
Prednisolone
/
Taux de survie
/
Études rétrospectives
/
Études de suivi
/
Mortalité
/
Lymphome T périphérique
/
Mesna
/
Survie sans rechute
/
Traitement médicamenteux
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Blood Research
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS